Opdivo Qvantig nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection Images
Generic Name: hyaluronidase/nivolumab
This medication has been identified as Opdivo Qvantig nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection. It is supplied by Bristol-Myers Squibb Company.
Opdivo Qvantig is used in the treatment of Colorectal Cancer; Esophageal Carcinoma; Gastric Cancer; Head and Neck Cancer; Hepatocellular Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Opdivo Qvantig nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Opdivo Qvantig
- Generic Name
- hyaluronidase/nivolumab
- Strength
- nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 00003-6120
More about Opdivo Qvantig (hyaluronidase / nivolumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.